Eli Lilly and Company (NYSE:LLY), a pharmaceutical powerhouse with a market capitalization of $683 billion and impressive gross margins of 83%, announced Wednesday that its diabetes medication Mounjaro (tirzepatide) demonstrated significant improvements in blood sugar control and body mass index (BMI) reduction in children and adolescents with type 2 diabetes.
In the Phase 3 SURPASS-PEDS trial, Mounjaro met its primary endpoint by reducing A1C levels by an average of 2.2% from baseline after 30 weeks of treatment, compared to a 0.05% increase with placebo. The trial included 99 participants aged 10 to under 18 years with type 2 diabetes inadequately controlled with metformin, basal insulin, or both.
Key secondary endpoints were also achieved, with 86.1% of participants on the 10 mg dose reaching a target A1C of 6.5% or lower. The 10 mg dose reduced BMI by 11.2% on average at 30 weeks, with improvements continuing through the 52-week extension period.
"Youth living with type 2 diabetes often face a more aggressive disease course," said Tamara Hannon, lead trial investigator and director of the Clinical Diabetes Program at Indiana University School of Medicine, in the company’s press release.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.